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Abstract
Tumor cells have increased metabolic requirements to maintain rapid growth. In particular, a highly lipogenic phenotype is
a hallmark of many tumor types, including prostate. Cancer cells also have increased turnover of nicotinamide adenine
dinucleotide (NAD
+), a coenzyme involved in multiple metabolic pathways. However, a specific role for NAD
+ in tumor cell
lipogenesis has yet to be described. Our studies demonstrate a novel role for the NAD
+-biosynthetic enzyme Nicotinamide
phosphoribosyltransferase (Nampt) in maintaining de novo lipogenesis in prostate cancer (PCa) cells. Inhibition of Nampt
reduces fatty acid and phospholipid synthesis. In particular, short chain saturated fatty acids and the phosphatidylcholine
(PC) lipids into which these fatty acids are incorporated were specifically reduced by Nampt inhibition. Nampt blockade
resulted in reduced ATP levels and concomitant activation of AMP-activated protein kinase (AMPK) and phosphorylation of
acetyl-CoA carboxylase (ACC). In spite of this, pharmacological inhibition of AMPK was not sufficient to fully restore fatty
acid synthesis. Rather, Nampt blockade also induced protein hyperacetylation in PC-3, DU145, and LNCaP cells, which
correlated with the observed decreases in lipid synthesis. Moreover, the sirtuin inhibitor Sirtinol, and the simultaneous
knockdown of SIRT1 and SIRT3, phenocopied the effects of Nampt inhibition on fatty acid synthesis. Altogether, these data
reveal a novel role for Nampt in the regulation of de novo lipogenesis through the modulation of sirtuin activity in PCa cells.
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Introduction
Nicotinamide adenine dinucleotide (NAD
+) is central to many
cellular processes. Synthesis of NAD
+ proceeds through multiple
pathways. Most tissues synthesize NAD
+ through the salvage of
nicotinamide by Nicotinamide phosphoribosyl transferase (Nampt)
[1,2]. Cancer cells have a high rate of NAD
+ turnover compared
to normal cells [3]. Accordingly, Nampt is essential for the survival
of tumor cells. Pharmacological blockade of Nampt reduces
viability in multiple types of cancer cells and can inhibit the growth
of tumor xenografts in vivo [3,4,5]. In addition, Nampt overex-
pression has been observed in several cancers, including prostate,
suggesting a key role in tumor biology [6,7,8,9,10]. Similarly,
Nampt expression increases the lifespan of non-transformed
mammalian cells [11,12,13]. Because of these findings, Nampt is
considered a rational target in cancer and several small molecule
inhibitors of the enzyme have been developed [3,14,15,16].
It has become apparent that NAD
+ has multiple roles in cellular
metabolism [17]. Several classes of enzymes utilize NAD
+ as a
substrate during their catalytic reactions. Prominent among them
are the sirtuin family of protein deacetylates [18]. Sirtuins regulate
the acetylation status of proteins, providing a rapid and efficient
way for tumor cells to respond to nutrient and energy changes in
the environment [19]. Proteomic analyses have identified over
2800 human proteins that can be acetylated [20]. Interestingly,
enzymes that participate in metabolic pathways are enriched
within the acetylated protein pool [21,22]. Among them, enzymes
in the fatty acid synthesis pathway were specifically identified [22].
Consistent with this, the mammalian acetyl-CoA synthetases
(AceCS1, AceCS2) are deacetylated and activated by SIRT1 and
SIRT3 [23,24]. Conversely, SIRT1 and SIRT3 also regulate fatty
acid oxidation via multiple acetylation substrates [25,26,27].
Further support for the role of sirtuins in fatty acid metabolism
is provided by the finding that mice deficient in the Sirt1 gene also
demonstrate increased phosphorylation of AMPK, an enzyme
central in the regulation of energy homeostasis and fatty acid
metabolism [28]. Collectively, these studies suggest that NAD
+
metabolism via Nampt and sirtuins may have a role in fatty acid
metabolism in cancer cells.
Tumors of multiple origins, including prostate, exhibit a
lipogenic phenotype that Is required for proliferation and survival
[29]. Increased de novo lipogenesis in tumors is achieved through
multiple mechanisms, ranging from gene amplification to post-
translational modifications [30,31,32,33,34]. Because of the
central role of lipogenesis in tumors, it is important to identify
new markers and pathways which facilitate this process to improve
our understanding of tumor biology. Because sirtuins regulate fatty
acid and lipid metabolism [23,24,25,27], and Nampt is required
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required for fatty acid and lipid metabolism in tumor cells. We
demonstrate that inhibition of Nampt and sirtuins reduces fatty
acid and lipid synthesis in tumor cells. Although Nampt inhibition
is associated with decreased ATP and AMPK activation, in our
system the effects on fatty acid synthesis were primarily mediated
by SIRT1 and SIRT3. Collectively, these data highlight a novel
convergence between NAD
+ metabolism, sirtuins, and lipogenesis
in prostate cancer. As a result, this study provides new insight into
metabolic control in tumor cells that could improve targeted
therapies for clinical intervention.
Materials and Methods
Materials
Antibodies against Acetylated Lysine (AcK), ACC, phospho-
ACC (S79), AMPK, phospho-AMPK (T172), SIRT1, SIRT3 and
AceCS1 were from Cell Signaling Technologies (Beverly, MA).
The antibody against fatty acid synthase (FASN) was from BD
Transduction Labs (San Diego, CA, USA). The antibody against
b-actin was from Sigma-Aldrich (St. Louis, MO, USA). The
antibody against Nampt (PBEF1, visfatin) was from Phoenix
Pharmaceuticals (Burlingame, CA, USA). Secondary antibodies
for goat-anti-rabbit or goat-anti-mouse were from BioRad
(Hercules, CA, USA). The Nampt inhibitor FK866 was provided
by the National Institute of Mental Health Chemical Synthesis
and Drug Supply Program (Rockville, MD, USA).
Cell Culture and Drug Treatments
PC-3, DU145, LNCaP, C4-2, Snb-19, and MCF-7 cells were
obtained from American Type Culture Collection (ATCC
Manassas, VA, USA). 3T3-Src cells were the generous gift of
Darren Seals and have been descried previously [36]. Cell culture
medium and supplements for tumor cell lines were supplied by
Invitrogen (Carlsbad, CA, USA). Normal prostate epithelial cells
(PRECs) and media were obtained from Lonza (Switzerland). PCa
cell lines were maintained in RPMI 1640 and Snb-19, 3T3-Src,
and MCF-7 cells were maintained in high glucose DMEM
supplemented with 10% fetal bovine serum (FBS), Penicillin
(100 Units/mL), and Streptomycin (100 mg/mL) at 37uC and 5%
CO2. PRECs were maintained in Clonetics media according to
the manufacturer’s instructions. Cells were treated at times and
concentrations indicated. FK866 was dissolved in DMSO and
vehicle control is 0.1% DMSO for treatments. NAD
+, nicotin-
amide mononucleotide (NMN), and nicotinic acid (Na) were
obtained from Sigma-Aldrich and dissolved in water. The sirtuin
inhibitor Sirtinol and the AMPK inhibitor Compound C were also
obtained from Sigma-Aldrich and dissolved in DMSO.
Western Blotting
Cells were treated as indicated and harvested, washed with cold
PBS, and lysed in buffer containing 1% Triton X-100, 20 mM
Tris-HCl, pH 8.3 and protease, phosphatase, and deacetylase
inhibitors (1 mM sodium orthovanadate and sodium fluoride,
200 nM okadaic acid, 5 mg/mL aprotinin, pepstatin, and leupep-
tin, 200 mM PMSF, 2 mg/mL Trichostatin A, 100 mM Sirtinol).
Protein samples were assayed with BioRad DC reagents, resolved
by SDS-PAGE, and transferred to Immobilon-P membrane
(polyvinylidene difluoride). Immunoreactive bands were detected
by enhanced chemiluminescence (Perkin Elmer Life Sciences,
Boston, MA, USA). For mitochondrial fractionation, cells were
lysed in hypotonic buffer (20 mM Hepes, 10 mM KCl, 250 mM
sucrose, 1.5 mM MgCl2 plus protease and phosphatase inhibitors)
using a Dounce homogenizer (Pestle B). Lysates were centrifuged
at 10,000 g for 20 minutes at 4uC and the pellet was collected and
lysed in buffer containing NP-40 alternative (1% w/v), glycerol
(10% v/v), 25 mM Hepes (pH 7.9), 100 mM NaCl, and 1 mM
EDTA with protease and phosphatase inhibitors. The supernatant
was centrifuged 16,000 g for 20 minutes at 4uC and collected as
the ‘‘cytoplasmic’’ fraction. The remaining pellet from the
cytoplasmic supernatant was resuspended in the NP-40 lysis
buffer described above as the ‘‘mitochondrial’’ fraction [37].
Total NAD, NADP, and ATP Quantification
Total cellular NAD was measured using the EnzyChrom Assay
Kit, (Hayward, CA, USA). Cells were seeded in triplicate in 6-well
plates (3610
5 cells/well). After 48 hours the cells were treated with
FK866 for another 48 hours and total NAD was determined
according to the manufacturer’s instructions. For total NADP
measurements, cells were treated as described above and
measurements were performed using the BioVision NADP
+/
NADPH Quantification Kit (Milpitas, California, USA) according
to the manufacturer’s instructions. Cellular ATP levels were
measured by bioluminescence using CellTiter-Glo from Promega
(Madison, WI, USA) according to the manufacturer’s instructions.
PCa cells were plated at 10
4 cells/well in Perkin Elmer white
polystyrene 96 well culture plates. Luminescence was normalized
to DNA content as detected by CyQUANT fluorescent reagent
from Invitrogen. Cells for the CyQUANT assay were plated and
treated in Costar black-walled 96 well plates (Corning Inc.,
Corning, NY, USA).
Cell Death Assays
PCa cells were plated at low density (800 cells per well of 6-well
plates) and treated for 24 hours in triplicate, as indicated. Cells
were maintained until visible colonies (.40 cells/colony) were
formed, then washed with PBS, fixed with methanol, stained with
crystal violet, and colonies were quantified by counting as
described previously [38]. For Trypan blue exclusion assays, cells
were grown in 6-well plates, and treated as indicated. Cells were
trypsinized until detached and the reaction was stopped with
culture media with serum. All cells were collected and resuspended
to equal volume in PBS. Trypan blue reagent was added for 10
minutes before counting. Live and dead cells were counted and
quantified as percent of total cells.
siRNA Knockdown
ON-TARGETplus siRNA oligonucleotide against Nampt
(GGUAAGAAGUUU CCUGUUA), SIRT1 (SIRT1.1
GCGAUUGGGUACCGAGAUA, SIRT1.2 GGAUAGGUC-
CAU AUACUUU) and SIRT3 (SIRT3.1 UUGAGAGAGU-
GUCGGGCAU, SIRT3.2 GGACCAGACAAAUAGGAUG)
and siGENOME Non-Targeting siRNA #2 were designed and
synthesized by Dharmacon (Lafayette, CO, USA). The siRNA
(100 nM) were transfected into cells with Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen). After 4
hours the transfection media was replaced with antibiotic-free
RPMI plus 10% FBS until cells were harvested for western blot
analysis or metabolic labeling.
Metabolic Labeling
To measure fatty acid synthesis, 10
5 cells per well were seeded
in 24-well plates (n=4 wells per treatment). Cells were treated
with FK866, Compound C, Sirtinol, NAD
+ metabolites, or
combinations thereof for 48 hours. For siRNA knockdown, cells
were transfected with siRNA and incubated for 4–5 days.
14C-
acetate (1 mCi) or
14C-choline (1 mCi) was added to each well for 2
Nampt Regulates Lipogenesis
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buffer (20 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 7.5),
and lipids were extracted using chloroform/methanol (2:1) as we
have previously described [38]. Newly synthesized lipids were
measured by scintillation counting and counts were normalized to
total protein.
Fatty Acid Methyl Ester (FAME) and Phospholipid
Analysis
PC-3 cells were seeded at 3610
5 cells/well of 6-well plates (n=3
wells per treatment) and after 48 hours cells were treated with
DMSO (0.1%), FK866 (100 nM), or FK866 plus NMN (500 mM)
for 48 hours. Cells were trypsinized, collected, and normalized to
cell number. Cell pellets were washed with cold 0.9% saline and
frozen in liquid nitrogen. Lipids were extracted using the Bligh-
Dyer method [39] and the combined fraction was stored at
280uC. For fatty acid analyses, an aliquot was combined with
internal standards (pentadecanoic acid (15:0) and heneicosanoic
acid (21:0)), evaporated under Argon gas, and resuspended in
ethanol. KOH (50%) was added to samples and incubated for 1
hour, 60uC. Non-saponifiable lipids were extracted with hexane
and discarded. The remaining phase was acidified with 6 M HCl
and lipids were recovered with 3 mL of hexane. After evaporating
the hexane, methanolic NaOH (0.5 M) was added and samples
were incubated for 5 minutes at 100uC. BF3 (14%) was added and
the solution was heated to 100uC for an additional 5 minutes.
After cooling, hexane (2 mL) and saturated aqueous NaCl (4 mL)
were added and vortexed. The hexane phase was recovered,
evaporated, and the residue was resuspended in 100 mL hexane
and samples were transferred to glass autosampler tubes for
analysis. The fatty acids were separated and quantified using a
DB-Wax column in a TSQ Quantum XLS triple quadrupole mass
spectrometer connected to a TRACE Ultra gas chromatograph
(GC-MS). Values were represented as mean picomoles of fatty
acid per nanomoles of phosphorous plus or minus standard
deviation.
For phospholipid analysis, lipids were extracted as described
above then resuspended in CHCl3:MeOH (1:1). To normalize
samples, total phosphorous levels for each sample were measured
from 50 mL aliquots as described by Rouser, et al. [40]. Lipids were
diluted to 2 nmol/mL lipid phosphorous with CHCl3:MeOH
including 1% formic acid. Glycerophospholipids were detected
using a TSQ Quantum Discovery Max electrospray tandem mass
spectrometer equipped with an Agilent 1100 LC. Phosphatidyl-
choline (PC) molecular species were measured by recording
precursors of m/z +184.1, phosphatidylethanolamine (PE) by
common neutral loss of 141 Da in the positive ion mode,
phosphatidylinositol (PI) by measuring by precursors of m/z 241 in
negative ion mode, and phosphatidylserine (PS) using the common
neutral loss of 185 Da as outlined by DeLong, et al. [41]. Lipid
species were excluded from further consideration if more than 1 of
the 3 replicates for any given treatment group was a zero value.
Molecular species were quantified as mol% of the class by
correcting for carbon isotope and mass-dependent ion throughput.
Lipid species are represented according to class and species as the
mean picomoles of lipid per nanomoles of phosphorous plus or
minus standard deviation. For each species we compared
phosphorous levels (pmol/nmol) among groups (DMSO/
FK866/FK+NMN) using one-way analysis of variance (ANOVA)
models. In order to avoid performing multiple tests with the
possibility of finding spurious results, pairwise comparisons were
only made between groups if the overall test from the ANOVA
was significant. When the overall ANOVA was significant post-
hoc pair-wise comparisons were performed between groups using
Student’s t-tests. Molecular species are defined as XX:Y where
XX refers to the sum of the carbons in the constituent fatty acids
and Y the total number of double bonds.
Statistical Analysis
Significance between groups was determined by ANOVA
followed by pair-wise Student’s t-tests and is defined as p,0.05.
Results
Nampt Activity Regulates PCa Cell NAD
+ Levels and
Survival
To investigate the role of Nampt in prostate cancer, protein
expression was determined in normal PREC, and tumorigenic C4-
2, LNCaP, DU145, and PC-3 cells by western blot. Nampt
expression was comparable across all cell lines (Figure 1A). Cell
fractionation demonstrated Nampt localization in the cytoplasmic
and mitochondrial compartments of prostate tumor cell lines
(Figure 1B). Pharmacological blockade of Nampt with the small
molecule active site inhibitor FK866 [3] reduced total NAD levels
to 26–43% of control levels after 48 hours, and levels were restored
by exogenous NAD
+ (*p,0.01, Figure 1C). Similarly, FK866
reduced total NADP to 23% of control, which was restored by
exogenous NAD
+ (Figure 1D). Although PRECs express Nampt,
viability was unaffected by FK866 treatment (Figure 1E). On the
other hand, FK866 induced cell death in 25% of LNCaP and in
50% of PC-3 cells (*p,0.01). The addition of exogenous NAD
+
prevented FK866-induced cell death (Figure 1E). Treatment with
FK866 also reduced clonogenic survival of PC-3 and DU145 cells
in a dose-dependent fashion, and clonogenic survival was also
rescued by exogenous NAD
+ (*p,0.01, Figure 1F).
In the salvage pathway, Nampt produces nicotinamide mono-
nucleotide (NMN) from nicotinamide. In the de novo pathway,
Nicotinic acid phosphoribosyltransferase (Naprt1) produces nico-
tinic acid mononucleotide (NaMN) from nicotinic acid (Na).
Western blot analysis demonstrated that Naprt1 was highly
expressed in DU145 cells but not PC-3 or LNCaP cells
(Figure 1G). Viability was also determined in PCa cells treated
with FK866 in the absence or presence of NMN (salvage) or Na (de
novo). Consistent with the western blot results, in DU145 cells
FK866-induced death was rescued by both NMN and Na
(*p,0.0001, Figure 1G). On the other hand, survival was only
restored by NMN and not Na in LNCaP and PC-3 cells
(*p,0.0001). These data indicate that NAD
+ synthesis is required
for the survival of PCa cells and while NAD
+ salvage through
Nampt predominates, the de novo pathway is active in at least one
cell line.
Nampt Activity is Required for Fatty Acid Synthesis
To determine if Nampt is required for the lipogenic phenotype
in tumor cells, de novo fatty acid synthesis was measured. Treatment
of PC-3 and DU145 cells with FK866 reduced fatty acid synthesis,
as measured by incorporation of
14C-acetate into lipid, by 90%
and 95%, respectively (*p,0.0001, Figure 2A). Consistent with the
effects on survival, NAD
+ and NMN restored fatty acid synthesis
in both cell lines. Similarly, Na restored fatty acid synthesis in
DU145 cells, but not PC-3 cells. Interestingly, treatment with
FK866 did not reduce fatty acid synthesis in LNCaP cells, despite
the reduction in NAD
+ levels (Figure 1B). Reduced fatty acid
synthesis was not associated with decreased expression of the fatty
acid synthesis enzymes ACC, AceCS1, or FASN. Treatment with
FK866 also reduced fatty acid synthesis in tumor cells of various
origins including Snb-19 glioblastoma cells, Src-transformed 3T3
cells (3T3-Src), and MCF-7 breast cancer cells by 90%, 91%, and
Nampt Regulates Lipogenesis
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e40195Figure 1. Nampt regulates NAD
+ levels and survival in PCa cells. (A) Nampt protein levels were determined by western blotting in PREC and
PCa cells. (B) Nampt localization was also determined in the cytoplasmic and mitochondrial fractions of PCa cells by western blot, with COX-IV as a
mitochondrial marker (C) Total NAD levels were measured in PCa cells after 48 hour treatment with vehicle (DMSO 0.1%), or FK866 (100 nM) in the
absence or presence of NAD
+ (100 mM) (*p,0.01). (D) Total NADP levels were measured in PC-3 cells after 48 hour treatment with vehicle (DMSO
0.1%), or FK866 (100 nM) in the absence or presence of NAD
+ (100 mM) (*p,0.01). (E) The effect of FK866 on survival was assessed by trypan blue
exclusion in PREC, LNCaP, and PC-3 cells after 48 hours of treatment. (F) Clonogenic survival of PC-3 and DU145 cells was measured following a dose-
response of FK866, or 100 nM FK866 plus NAD
+ (100 mM) for 24 hours (*p,0.01). (G) Expression of Naprt1 and b-actin were determined by western
blot. The ability of NMN and Na to protect cells from FK866 was determined by trypan blue exclusion in LNCaP cells (48 hour treatment) and
clonogenic survival in PC-3 and DU145 cells (24 hour treatment).
doi:10.1371/journal.pone.0040195.g001
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NAD
+ and NMN restored fatty acid synthesis in these cells.
Transfection of PC-3 cells with Nampt-specific siRNA also
reduced fatty acid synthesis by 62% compared to cells transfected
with scrambled siRNA (*p,0.0001, Figure 2C).
Fatty acid methyl ester (FAME) analysis was performed to
determine how Nampt inhibition affected the fatty acid profile of
PC-3 cells (Figure 2D). Inhibition of Nampt significantly reduced
the levels of the de novo synthesized 14:0 and 16:0 fatty acid species
to 57% and 83% of control, respectively, and the 16:1 fatty acid
species to 81% of control (*p,0.05, DMSO versus FK866).
Exogenous NMN restored these fatty acids back to control levels.
Because de novo synthesized fatty acids decreased, the relative levels
of the long chain and polyunsaturated fatty acids species
Figure 2. Nampt activity is required for fatty acid synthesis in cancer cells. (A) PCa cells were treated with FK866 (100 nM) in the absence or
presence of NAD
+, NMN, or Na for 48 hours and fatty acid synthesis was determined by the incorporation of
14C-acetate into the lipid (*p,0.0001).
Expression of ACC, AceCS1, FASN, and b-actin was determined by western blot. (B) Fatty acid synthesis was measured in Snb-19 glioblastoma cells,
Src-transformed 3T3 fibroblasts, and MCF-7 breast cancer cells as in (A) (*p,0.0001). (C) PC-3 cells were transfected with scrambled or Nampt-
targeting siRNA (100 nM) and fatty acid synthesis was assayed 5 days post-transfection (*p,0.0001). (D) PC-3 cells were treated as indicated and the
fatty acid profile was determined by GC-MS.
doi:10.1371/journal.pone.0040195.g002
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of Nampt activity reduces de novo fatty acid synthesis.
The effect of Nampt inhibition on lipid metabolism was also
assessed by
14C-choline incorporation into lipid. Treatment with
FK866 reduced incorporation of
14C-choline into lipid by 75% in
PC-3 cells and 82% in DU145 cells (*p,0.001, Figure 3A).
Interestingly, FK866 treatment also reduced incorporation of
14C-
choline into lipid by 80% in LNCaP cells (*p,0.001). This
suggests that fatty acid and lipid metabolism may be differentially
regulated by NAD
+ in LNCaP cells. Therefore, Nampt activity
appears to be required for choline incorporation into lipids in PCa
cells, independent of fatty acid synthesis. Knockdown of Nampt
recapitulated the effects of FK866 on lipogenesis. Transfection of
PC-3 cells with Nampt-specific siRNA reduced lipid synthesis by
55% relative to cells transfected with scrambled siRNA
(*p,0.0001, Figure 3B).
The cellular phospholipid profile was determined by mass
spectrometry in PC-3 cells following Nampt inhibition. Interest-
ingly, FK866 treatment primarily affected phosphatidylcholine
(PC) metabolism, altering 23 out of 32 species (Figure 3C,
*p,0.05, DMSO versus FK866). On the other hand, within the
phosphatidyl -ethanolamine (PE), -inositide (PI), and -serine (PS)
classes of phospholipids, only 4 of 52 detected species were
significantly changed (Figure 4A–C). Of the 23 PC species that
were affected by FK866 treatment, 8 decreased and 15 increased.
The PC species reduced by Nampt inhibition were 30:0 PC, 30:1
PC, 32:0 PC, 32:1 PC, 32:2 PC, 34:2 PC and the ether lipid
species e32:1 PC, and e34:1 PC. Most of the decreased species
were restored to control levels by exogenous NMN. The species
most affected were 30:0 PC, 30:1 PC, and 32:0 PC which were
reduced to 41%, 48%, and 42% of control levels, respectively. Of
note, the fatty acid substituents that comprise the PC species
reduced by Nampt inhibition correspond to the 14:0, 16:0, and
16:1 fatty acid species that were also decreased in the FAME
analysis (Figure 2D). The 15 PC species that increased with Nampt
inhibition were 36:1 PC, 36:4 PC, 38:3 PC, 38:4 PC, 38:5 PC,
38:6 PC, 40:5 PC, 40:6 PC, 40:7 PC, and the ether lipid species
e32:2 PC, e36:4 PC, e36:5 PC, e38:4 PC e38:5 PC, and e38:6 PC.
The fatty acid substituents in the increased PC species also
correspond to those that increased with FK866 treatment.
Furthermore, most of the PC species that increased contained a
polyunsaturated fatty acid (PUFA) in their composition. Among
the PS, PE and PI classes, 40:4 PS levels increased, while 38:7 PE,
36:1 PI, and 36:2 PI levels decreased (*p,0.05). Interestingly,
although 36:1 PI levels decreased, the equivalent PC species
increased, and the levels of 36:2 PI decreased with no difference in
Figure 3. Nampt activity is required for phosphatidylcholine (PC) synthesis in cancer cells. (A) PCa cells were treated for 48 hours with
vehicle, or FK866 (100 nM) in the absence or presence of NAD
+ (100 mM) and lipid synthesis was assessed by
14C-choline incorporation (*p,0.0001).
(B) PC-3 cells were transfected with scrambled or Nampt-targeting siRNA (100 nM) and lipid synthesis was assayed 5 days post-transfection
(*p,0.0001). (C) PC-3 cells were treated as indicated and the PC profile was determined by mass spectrometry (*p,0.05).
doi:10.1371/journal.pone.0040195.g003
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inhibition on lipid synthesis primarily manifest through PC
metabolism, suggesting that specific metabolic and signal trans-
duction pathways may be regulated by NAD
+ synthesis.
Inhibition of Nampt Activates AMPK
Because Nampt regulates mitochondrial function and energy
homeostasis, the effect of Nampt inhibition on ATP levels and
AMPK activation was ascertained. Treatment with FK866
reduced ATP in a dose-dependent manner. Treatment with
10 nM and 100 nM FK866 for 48 hours reduced ATP levels to
29% and 22% of control, respectively, in PC-3 cells and to 46%
and 8% of control, respectively, in DU145 cells (*p,0.0001,
Figure 5A). Although Nampt inhibition reduced NAD
+ levels in
LNCaP cells (Figure 1B), treatment with FK866 did not reduce
ATP levels. Decreased ATP can result in activation of AMPK and
subsequent phosphorylation and inactivation of ACC [42].
Concomitant with decreased ATP levels, Nampt inhibition
increased phosphorylation of ACC at serine 79 12-fold in PC-3
cells and 21-fold in DU145 cells (Figure 5B). Phosphorylation of
ACC was prevented by co-treatment with NAD
+ in both cell lines.
Consistent with our previous results, Nampt inhibition did not
induce phosphorylation of ACC in LNCaP cells.
PC-3 cells were then treated with vehicle or FK866 in the
absence or presence of the AMPK inhibitor Compound C. As
expected, FK866 increased pACC and pAMPK levels 4.7-fold and
5.5-fold over control, respectively (Figure 5C). Co-treatment with
Compound C reduced pACC and pAMPK to control levels. On
the other hand, Compound C only had a modest restorative effect
on fatty acid synthesis in FK866 treated cells. Compound C
restored fatty acid synthesis in FK866 treated cells from 5% of
control to 22% of control (*p,0.0001, DMSO vs. FK866,
#p=0.0007 FK866 vs. FK+CC, Figure 5D). Compound C was
also unable to restore survival in FK866 treated cells (*p,0.0001).
These data suggest that the effects of Nampt inhibition on
lipogenesis correlate with AMPK activation and phosphorylation
of ACC, but are also mediated by an AMPK-independent
mechanism.
Sirtuins Regulate de Novo Lipogenesis
Nampt is required for sirtuin activity in mammalian cells [35].
In addition, SIRT1 and SIRT3 each deacetylate and activate
mammalian acetyl-CoA synthetases, allowing for entry of acetate
into the fatty acid synthesis pathway [23,24]. Therefore, we
reasoned that the impact of Nampt inhibition on lipogenesis would
be mediated by sirtuins in tumor cells. Indeed, blockade of Nampt
activity increased global protein acetylation (AcK) levels by 1.8-
fold in PC-3 cells, 1.9-fold in DU145 cells, and 3-fold in LNCaP
cells (Figure 6A), supporting previous observations that Nampt can
regulate sirtuin function [35]. Although we were unable to detect
acetylation of AceCS1 following Nampt inhibition in PCa cells
(data not shown), inhibition of sirtuin activity with Sirtinol reduced
14C-acetate incorporation into fatty acids by 57%, 74%, and 92%
in PC-3, DU145, and LNCaP cells, respectively (Figure 6B).
Sirtinol also reduced the incorporation of
14C-choline into lipids
by 86%, 87%, and 78% in PC-3, DU145, and LNCaP cells,
respectively (*p,0.0001, Figure 6B). Because SIRT1 and SIRT3
are known to deacetylate and activate mammalian acetyl-CoA
synthetases, fatty acid synthesis was measured following knock-
down of SIRT1 and SIRT3 [23,24]. Knockdown of SIRT1 or
SIRT3 individually by siRNA did not reduce fatty acid synthesis
(Figure 6C). On the other hand, simultaneous knockdown of
SIRT1 and SIRT3 reduced incorporation of acetate into fatty
acids by 28% in PC-3 cells, and 37% in LNCaP cells (*p=0.0002,
Figure 6D). Interestingly, choline incorporation was not reduced
by SIRT1/3 knockdown. Taken together, these data suggest that
the effect of Nampt inhibition on lipogenesis is conferred by
decreased sirtuin activity.
Discussion
Nampt has garnered attention as a potential therapeutic target
in cancer and other metabolic diseases [17]. Nampt expression is
high in several cancers and its activity is required for tumor cells to
proliferate and survive [5,8,9,10]. Nampt has been implicated in
the control of sirtuin activity, mitochondrial function, and cellular
lifespan [11,12,13,35]. The metabolic pathways in cancer cells that
are specifically regulated by Nampt and NAD
+ synthesis have not
been described in depth, however. Previous studies show that
Nampt inhibition has no effect on glucose metabolism in tumor
cells [4,9]. The data presented above, however, detail the novel
observation that Nampt is required for fatty acid and lipid
synthesis in tumor cells through sirtuin-dependent mechanisms.
Pharmacologic blockade of Nampt as well as siRNA-mediated
knockdown impaired lipogenesis in most cell lines. Similarly,
Sirtinol treatment inhibited fatty acid and lipid synthesis in all
prostate tumor cell lines tested. Additionally, simultaneous
knockdown of SIRT1 and SIRT3 also reduced fatty acid synthesis
in PC-3 and LNCaP cells. Taken together, these data demonstrate
that Nampt and sirtuin activities are required for de novo lipogenesis
in cancer cells. It is worth noting that the Nampt substrate
nicotinamide (Nam) also inhibits sirtuins [43]. Accordingly, it is
possible that Nampt inhibition could limit sirtuin activity through
accumulation of Nam and reduced NAD
+ levels. The impact of
Nampt inhibition on Nam levels was not determined in our study,
however. Moreover, the addition of NMN to all cell lines, and Na
to DU145 cells, prevented the effects of Nampt inhibition on cell
death and lipid synthesis. These data, along with the finding that
knockdown of SIRT1 and 3 also inhibit lipogenesis, suggest that
the effects of Nampt inhibition on sirtuin activity are primarily
through depletion of NAD
+ levels rather that accumulation of
Nam.
Inhibition of Nampt induces activation of AMPK and
phosphorylation of ACC. These data are consistent with the fact
that NAD
+ is required for ATP production and subsequent energy
homeostasis in tumor cells. Additionally, SIRT1 and SIRT3 have
both been implicated in the control of fatty acid oxidation (FAO)
by deacetylation of multiple enzymes [25,26,27]. Because FAO
has come to the forefront as an important aspect of energy control
and survival in tumor cells, it is possible that Nampt inhibition also
inhibits FAO, leading to activation of AMPK. Although AMPK
activation and phosphorylation are important regulatory steps in
fatty acid synthesis, our data demonstrate that phosphorylation is
not the only step that reduces fatty acid synthesis. Pharmacological
blockade of AMPK with Compound C reduced ACC phosphor-
ylation without fully restoring fatty acid synthesis. These data
illustrate that protein acetylation acts in parallel with ACC
phosphorylation to limit fatty acid synthesis when Nampt activity
is inhibited. Previous studies show that acetylation and phosphor-
ylation of the transcription factors FOXO1 and STAT1 can occur
simultaneously resulting in altered function [44,45]. It is likely that
that one event does not control the other, rather, that acetylation
and phosphorylation serve as back-up mechanisms for one
another. Nampt inhibition also reduced the levels of NADPH,
an essential cofactor for FASN function. Thus, by affecting energy
homeostasis, protein acetylation, and cofactor concentration, our
data reveal a multi-factorial role for Nampt in the regulation of
tumor cell lipogenesis.
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e40195Our data demonstrate that SIRT1 and SIRT3 coordinately
regulate fatty acid synthesis in tumor cells. Because simultaneous
knockdown of SIRT1 and SIRT3 was required to inhibit fatty acid
synthesis, it suggests that the two enzymes have redundant
functions in the pathway. This is consistent with previous findings
that SIRT1 and SIRT3, but no other sirtuin family members,
Figure 4. Nampt inhibition does not affect the phosphatidylserine (PS), phosphatidylethanolamine (PE), or phosphatidylinositol
(PI) lipid classes. (A–C) PC-3 cells were treated with vehicle, FK866 (100 nM) in the absence or presence of NMN (500 mM) for 48 hours and the PS,
PE, and PI profiles were determined by mass spectrometry (*p,0.05).
doi:10.1371/journal.pone.0040195.g004
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e40195deacetylate AceCS1 and AceCS2 [23,24]. Although we were
unable to detect acetylation of acetyl-CoA synthetases (not shown),
these data, together with previous reports, are consistent with the
notion that AceCS1 and AceCS2 are acetylated when Nampt
activity is blocked. However, the data do not rule out the
possibility that other lipogenic enzymes are affected by Nampt
inhibition. There are several examples of other protein substrates
that are recognized by multiple sirtuins, including the cancer-
related proteins p53, FOXO1, and NF-kB [46,47,48]. A
redundancy mechanism also exists in breast cancer cells whereby
silencing of both SIRT1 and SIRT2 is required to induce cell
death [49]. As mentioned, it is also possible that other lipogenic
enzymes are affected by Nampt inhibition and sirtuin blockade.
For example, an analysis of the human liver protein acetylome
identified ACC, the rate-limiting enzyme of fatty acid synthesis,
and FASN, the enzyme that synthesizes fatty acids, as potential
targets for acetylation [22]. This suggests that fatty acid synthesis
may be regulated at multiple levels by acetylation. It is interesting
that Nampt blockade did not affect fatty acid synthesis in LNCaP
cells. Treatment with FK866 reduced total NAD
+ levels in LNCaP
cells as efficiently as in PC-3 and DU145 cells, without reducing
ATP levels or fatty acid synthesis. On the other hand, Sirtinol
Figure 5. Inhibition of Nampt activates AMPK signaling. (A) Prostate tumor cells were treated with vehicle, FK866 (10 nM or 100 nM), or FK866
(100 nM) plus NAD
+, Na or NMN. After 48 hours, ATP levels were measured by luminescence and normalized to DNA content (*p,0.0001). (B) The
levels of pACC and ACC were determined in cells treated with vehicle (0.1%), or FK866 (100 nM) in the absence or presence of NAD
+ for 48 hours
(100 mM). (C) PC-3 cells were treated with vehicle, FK866 (100 nM), Compound C (CC, 10 mM), or the combination of both (FK+CC) for 48 hours and
pACC, ACC, pAMPK, and AMPK levels were determined by western blot. (D) PC-3 cells were treated with vehicle, FK866, Compound C, or the
combination of both for 48 hours and fatty acid synthesis was measured (*p,0.0001, #p=0.0007). Cell killing was also determined by trypan blue
exclusion (*p,0.0001).
doi:10.1371/journal.pone.0040195.g005
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e40195Figure 6. Sirtuin activity is required for lipogenesis in prostate cancer cells. (A) PCa cells were treated as indicated for 48 hours and global
protein acetylation was measured by western blot. (B) PCa cells were treated with DMSO (0.1%) or Sirtinol (100 mM) for 48 hours and
14C-acetate and -
choline incorporation into lipid were measured (*p,0.0001). (C) PC-3 cells were treated with scrambled, SIRT1, or SIRT3 targeting siRNA (100 nM
each) and fatty acid synthesis was measured. The expression levels of SIRT1, SIRT3, and b-actin were determined by western blot. (D) PC-3 and LNCaP
cells were transfected with scrambled (200 nM) or the combination of SIRT1.2 and SIRT3.2 targeting siRNA (100 nM each). The incorporation of
14C-
acetate and -choline into lipid were determined 5 days after transfection (*p=0.0002). The levels of SIRT1, SIRT3, and b-actin were determined by
western blot.
doi:10.1371/journal.pone.0040195.g006
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synthesis. These data demonstrate that NAD
+ metabolism is
important for lipogenesis in cancer cells. There is at least one
report demonstrating that in some cell lines mitochondrial NAD
+
levels are insensitive to the effects of FK866. Thus, it is possible
that mitochondria in LNCaP cells are relatively unaffected by
FK866. This would explain why ATP levels and fatty acid
synthesis would not be decreased by FK866 in LNCaP cells. Some
cell lines also appear to not express Nampt in the mitochondria,
making them less susceptible to Nampt inhibition, although this is
not the case in LNCaP cells [50]. Deciphering the precise
mechanism by which fatty acid synthesis is regulated by NAD
+ in
tumor cells will lead to a greater understanding of the complex
mechanisms of tumor cell metabolism, and how NAD
+ metabo-
lism contributes to cancer pathogenesis.
The effect of Nampt inhibition on lipid metabolism is especially
evident within the PC class of glycerophospholipids where there
was an overall shift from higher levels of saturated and mono-
unsaturated PC species to a composition enriched in poly-
unsaturated species. This is similar to the effects on the lipid
profile of cells in which FASN and ACC activities have been
inhibited [51,52]. A distinction of these data is that the effect of
Nampt inhibition is primarily concentrated with the PC class of
lipids, whereas FASN and ACC inhibition also impact the other
lipid classes. A previous study also demonstrated Nampt inhibition
results in decreased phosphocholine levels, suggesting the possi-
bility that choline kinase may be inhibited [53]. It is intriguing to
speculate that choline kinase may be acetylated when Nampt is
inhibited, although we were unable to detect choline kinase
acetylation in lysates from cells treated with FK866 (not shown).
There is also evidence that choline-phosphate cytidylyltransferase
1b in the Kennedy pathway of PC synthesis is acetylated in human
liver tissue samples [22]. The data presented in this study, along
with previous reports, demonstrates that PC synthesis also appears
to be subject to metabolic regulation by Nampt and acetylation.
We demonstrate that fatty acid synthesis can be inhibited by
Sirtinol and by silencing of SIRT1 and SIRT3, whereas lipid
synthesis was only blocked by Sirtinol but not SIRT1/3
knockdown. The data demonstrate that fatty acid and lipid
synthesis are differentially regulated by multiple sirtuins, which
likely have redundant functions. It is also worth noting that Nampt
inhibition reduced lipid synthesis in LNCaP cells, but not fatty acid
synthesis. Because LNCaP cells did not activate AMPK or
phosphorylate ACC when Nampt was inhibited, the effects on
lipid metabolism appear to be independent of AMPK. This further
supports the notion the PC metabolizing enzymes may be
acetylated when Nampt is inhibited.
Collectively, we have identified a novel connection between
Nampt, NAD
+ metabolism, and lipogenesis. Because of the
detrimental side effects of standard therapies for the treatment of
PCa, Nampt blockade could serve as a novel therapeutic strategy
to inhibit fatty acid synthesis and induce tumor cell death, while
preserving normal organ function. FK866 has undergone a Phase
I clinical trial for solid malignancies and several NAD
+ synthesis
inhibitors are also currently under development [16,54,55,56].
Sirtuin inhibitors also have promise as anti-cancer drugs
[57,58,59,60]. Additionally, AMPK activators also have promise
against multiple cancers. Because Nampt inhibition affects AMPK
and sirtuins, Nampt inhibitors could yield an efficient mode of
blocking tumor growth. This growing preclinical evidence,
combined with the development of new and effective Nampt
inhibitors, could provide a novel avenue for metabolic repro-
gramming and enhance strategies for cancer therapy.
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